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ABSTRACT
Fabry disease (FD) is an X-linked inborn error of glycosphingolipid metabolism due to the
deficiency of α-galactosidase A. The progressive accumulation of globotriaosylceramide (Gb3),
particularly in the vascular endothelium, leads to renal, cardiac, and cerebrovascular
manifestations and early death. Clinical manifestations include the onset of pain and paresthesias
in extremities, angiokeratoma and hypohidrosis during childhood or adolescence. Proteinuria
and lymphedema occur with increasing age. Severe renal impairment leads to hypertension and
uremia. Death usually occurs due to renal failure or cardiac or cerebrovascular disease. Disease
presentation may be subtle, and its signs and symptoms are often discounted as malingering or
are mistakenly attributed to other disorders, such as rheumatic fever, neurosis, multiple sclerosis,
lupus, or petechiae.
We present a 46-year-old man who since adolescence has suffered from painful
acroparesthesia, disseminated skin angiokeratomas, hypohidrosis and heat intolerance. He was
submitted to a thorough investigation with different specialists, but never reached a diagnosis.
He started hemodialysis 3 years ago and at the moment is in standby for kidney transplantation.
He was enrolled in a Brazilian FD screening and a reduced serum activity of α-galactosidase A
(0.0027 nmol/h/mL – reference value 4-22) confirmed the diagnosis of FD.
He has angiokeratoma at the bottom area, his echocardiogram demonstrated left ventricular
hypertrophy and the family history is very rich, as the patient has 15 siblings.
This case represents a very common story for FD patients. They usually spend most of
their lives trying to find someone who could understand or explain their suffering. These results
indicate that FD may be much more common among male dialysis patients than previously
recognized. Subsequently, FD should be considered in every patient with unexplained renal
disease, especially when cardiac or cerebral complications suggest an underlying multisystemic
disorder. Early diagnosis of FD is important because it allows family studies to identify other
affected relatives for genetic counseling and therapeutic intervention.
Keywords: Chronic kidney disease, enzyme replacement therapy, Fabry disease,
angiokeratoma corporis diffusum, α-galactosidase, agalsidase, lysosomal diseases, renal
dysfunction.
RESUMO
A doença de Fabry (DF) é um erro inato do metabolismo dos glicoesfingolipídeos devido à
deficiência da α-galactosidase A. O acúmulo progressivo de globotriaosilceramida (Gb3),
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particularmente no endotélio vascular, leva a manifestações renais, cardíacas e cerebrovasculares
e morte precoce. As manifestações clínicas incluem o início, durante a infância ou adolescência,
de episódios de dor e parestesias nas extremidades, angioqueratomas e hipohidrose. Com a
idade, podem aparecer proteinúria e linfedema. Insuficiência renal grave leva à hipertensão e
uremia. O óbito ocorre devido à insuficiência renal ou doença cardíaca ou cerebrovascular. A
apresentação da doença pode ser sutil, e seus sinais e sintomas são erroneamente atribuídos
a outras doenças, como febre reumática, neurose, esclerose múltipla, lúpus ou petéquias.
Relatamos o caso de um paciente masculino com 46 anos que, desde a adolescência,
sofre de acroparestesia, angioqueratomas disseminados, hipohidrose e intolerância ao calor.
Ele foi submetido a extensa investigação com diferentes especialistas, mas nunca chegou a um
diagnóstico. Iniciou hemodiálise há 3 anos e, no momento, está na lista de espera para transplante
de rim. Participou de um programa brasileiro de triagem para DF, e uma atividade reduzida de α-
galactosidase A (0,0027 nmol/h/mL – valor de referência 4-22) confirmou o diagnóstico de DF.
O paciente apresenta angioqueratomas na área do calção, seu ecocardiograma demonstra
hipertrofia ventricular esquerda e sua história familiar é rica, pois ele tem 15 irmãos.
Este caso representa uma história muito comum entre pacientes com DF. Eles geralmente
passam a maior parte de suas vidas tentando encontrar alguém que compreenda ou explique
seu sofrimento. Estes resultados indicam que a DF pode ser muito mais comum entre homens
que realizam hemodiálise do que antes previsto. Subseqüentemente, a DF deve ser considerada
em todo paciente com doença renal sem causa aparente, principalmente quando complicações
cardíacas ou cerebrovasculares sugerirem uma doença multissistêmica. O diagnóstico precoce
da DF é importante, pois permite estudo familiar para identificar parentes afetados para
aconselhamento genético e intervenção terapêutica.
Unitermos: Doença renal crônica, terapia de reposição enzimática, doença de Fabry,
angioqueratoma corporis diffusum, α-galactosidase, agalsidase, doenças lisossômicas, disfunção
renal.
INTRODUCTION
Fabry disease (FD) is an X-linked inborn error of
glycosphingolipid metabolism due to the deficiency of
α-galactosidase A. Reduced activity of α-galactosidase
A causes storage of globotriaosylceramide (Gb3) inside
cell lysosomes. Its progressive accumulation, particularly
in the vascular endothelium, leads to renal, cardiac, and
cerebrovascular manifestations and early death. The
disease is panethnic, and incidence estimates range from
about 1 in 40,000 to 60,000 males (1).
Clinical manifestations in classically affected
hemizygotes who have no detectable α-galactosidase
A activity include the onset of pain and paresthesias
in extremities, vessel ectasia (angiokeratoma) in skin
and mucous membranes, and hypohidrosis during
childhood or adolescence. Corneal and lenticular
opacities are also early findings. Proteinuria and
lymphedema occur with increasing age. Severe renal
impairment leads to hypertension and uremia. Death
usually occurs due to renal failure or cardiac or
cerebrovascular disease. Some of these manifestations
have been already studied by us (2-4).
Although clinical onset occurs in childhood,
disease presentation may be subtle, and its signs and
symptoms are often discounted as malingering or are
mistakenly attributed to other disorders, such as
rheumatic fever, neurosis, multiple sclerosis, lupus, or
petechiae.
FD predominantly affects males, but in contrast
to some other diseases with X-linked inheritance, most
female heterozygotes are also affected but do not always
present with the classic phenotype.
CASE REPORT
We present a 46-year-old man who since
adolescence has suffered from painful acroparesthesia,
disseminated skin angiokeratomas, hypohidrosis and
heat intolerance.
During his life, he has been submitted to a
thorough investigation with different specialists, but
never reached a diagnosis. Three years ago he was
diagnosed with renal insufficiency, progressing to end-
stage renal disease 1 year ago when he started
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hemodialysis. At the moment, he is in standby for kidney
transplantation. He also has left ventricular hypertrophy
and impaired vision.
This patient was enrolled in a Brazilian FD
screening and a reduced serum activity of α-galactosidase
A (0.0027 nmol/h/mL – reference value 4-22) confirmed
the diagnosis of FD.
On physical examination the patient was
normotensive, and his body weight was 61.500 kg.
Cutaneous lesions were located at the bottom area.
These lesions were first noticed during adolescence, and
progressively increased in number with time.
His echocardiogram demonstrated left ventricular
hypertrophy, but his electrocardiogram (EKG) did not
show conduction abnormalities. Serum creatinine was
6.8 mg/dL (normal range 0.6-1.3), urea 74 mg/dL (nor-
mal range 13-43). A biopsy of the kidney revealed tubular
atrophy, interstitial fibrosis and glomerular sclerosis.
The family history is very rich, as the patient has
15 siblings. He has a brother who died of renal failure at
35. Genetic counseling was able to identify one nephew
who also has reduced serum activity of α-galactosidase
A (0.05 nmol/h/mL – reference value 4-22), with only
mild symptoms of FD. Molecular analysis is under way
to diagnosis the female relatives.
DISCUSSION
This case represents a very common story for Fabry
patients. They usually spend most of their lives trying to
find someone who could understand or explain their
suffering.
Because FD is not common or well known and its
early classical manifestations tend to be nonspecific, the
disorder is often unrecognized, misdiagnosed, or
diagnosed late in life. Males with classical phenotype
typically present in childhood with the characteristic
angiokeratoma and acroparesthesias. However, if these
signs and symptoms are subtle or absent, the disorder
may not be recognized until adulthood, when
proteinuria, renal insufficiency, and/or cardiomyopathy
are detected and the diagnosis is belatedly made (5).
Renal involvement has been recognized as a cardi-
nal feature of FD, since patients with characteristic skin
lesions and albuminuria were first described in 1898 (6).
The renal manifestation results from GL3
deposition in podocytes, mesangium, glomerular
endothelium, epithelium of the loop of Henle and the
distal tubule, arterial and arteriolar endothelial and
smooth muscle cells, and interstitial cells (7). The
deposition in the renal vascular endothelium is
progressive and associated with interstitial fibrosis and
glomerulosclerosis (8). End-stage renal disease usually
occurs in the third to fifth decade of life (9).
Screening efforts can be carried out in
subpopulations thought to be at higher risk for the disease
than the general population. Dialysis screening efforts
seem to be worthwhile, since kidney failure is an
important outcome in FD. Nakao et al. (10) screened
514 consecutive males and found six who had low levels
of serum α-galactosidase, for a prevalence of 1.2%. Large
scale screening efforts of dialysis populations have been
carried out in the Netherlands and Austria.
These results indicate that FD may be much more
common among male dialysis patients than previously
recognized. Apparently, FD is seldom recognized as a
cause of renal failure and, as a consequence, is possibly
underdiagnosed. Subsequently, FD should be considered
in every patient with unexplained renal disease,
especially when cardiac or cerebral complications suggest
an underlying multisystemic disorder.
In males FD can reliably be diagnosed by α-
galactosidase A activity determination. This could then
be followed by screening of family members for FD, in
whom progression of renal failure or other organ failure
due to disease may be detected at an earlier stage,
enabling appropriate intervention.
Early diagnosis of FD is important because it allows
family studies to identify other affected relatives for
genetic counseling and therapeutic intervention. This
is especially true now that clinical studies have shown
the safety and effectiveness of enzyme replacement
therapy for FD (11,12), as well as the potential for
enzyme enhancement therapy (13).
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